- Home
- ATOS vs COYA Comparison
ATOS vs COYA Comparison
Compare ATOS & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- COYA
- Stock Information
- Founded
- ATOS 2009
- COYA 2020
- Country
- ATOS United States
- COYA United States
- Employees
- ATOS N/A
- COYA N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- COYA Health Care
- Exchange
- ATOS Nasdaq
- COYA Nasdaq
- Market Cap
- ATOS 107.2M
- COYA 107.0M
- IPO Year
- ATOS 2012
- COYA 2022
- Fundamental
- Price
- ATOS $0.84
- COYA $6.05
- Analyst Decision
- ATOS Strong Buy
- COYA Strong Buy
- Analyst Count
- ATOS 3
- COYA 4
- Target Price
- ATOS $6.17
- COYA $16.50
- AVG Volume (30 Days)
- ATOS 473.0K
- COYA 99.1K
- Earning Date
- ATOS 11-11-2025
- COYA 11-05-2025
- Dividend Yield
- ATOS N/A
- COYA N/A
- EPS Growth
- ATOS N/A
- COYA N/A
- EPS
- ATOS N/A
- COYA N/A
- Revenue
- ATOS N/A
- COYA $423,452.00
- Revenue This Year
- ATOS N/A
- COYA N/A
- Revenue Next Year
- ATOS N/A
- COYA N/A
- P/E Ratio
- ATOS N/A
- COYA N/A
- Revenue Growth
- ATOS N/A
- COYA N/A
- 52 Week Low
- ATOS $0.55
- COYA $4.65
- 52 Week High
- ATOS $1.66
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- COYA 43.93
- Support Level
- ATOS $0.81
- COYA $6.05
- Resistance Level
- ATOS $0.80
- COYA $6.53
- Average True Range (ATR)
- ATOS 0.03
- COYA 0.48
- MACD
- ATOS 0.01
- COYA -0.06
- Stochastic Oscillator
- ATOS 92.67
- COYA 17.31
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.